BUSPAR Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Buspar, and when can generic versions of Buspar launch?

Buspar is a drug marketed by Bristol Myers Squibb and is included in two NDAs.

The generic ingredient in BUSPAR is buspirone hydrochloride. There are nineteen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the buspirone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Buspar

A generic version of BUSPAR was approved as buspirone hydrochloride by IMPAX LABS INC on March 28^th, 2001.

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for BUSPAR?
What are the global sales for BUSPAR?
What is Average Wholesale Price for BUSPAR?

Summary for BUSPAR

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	20
Patent Applications:	646
DailyMed Link:	BUSPAR at DailyMed

Drug patent expirations by year for BUSPAR

Recent Clinical Trials for BUSPAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Rehabilitation Hospital	Phase 2
National Institute of Neurological Disorders and Stroke (NINDS)	Early Phase 1
University of Louisville	Early Phase 1

See all BUSPAR clinical trials

US Patents and Regulatory Information for BUSPAR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-001	Dec 20, 2000		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-003	Apr 22, 1996		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	CAPSULE;ORAL	021190-004	Dec 20, 2000		DISCN	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for BUSPAR

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-002	Sep 29, 1986	3,717,634	⤷ Subscribe
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-003	Apr 22, 1996	6,150,365*PED	⤷ Subscribe
Bristol Myers Squibb	BUSPAR	buspirone hydrochloride	TABLET;ORAL	018731-004	Apr 22, 1996	6,150,365*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for BUSPAR

See the table below for patents covering BUSPAR around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
New Zealand	520823	Anxiety method	⤷ Subscribe
Hungary	201322	PROCESS FOR PRODUCING PHARMACEUTICALLY APPLICABLE P 188 POLYMORPHOUS MODIFICATION OF BUSPIRON HYDROCHLORIDE	⤷ Subscribe
Yugoslavia	42100		⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for BUSPAR

Recent Clinical Trials for BUSPAR

Make Better Decisions: Try a trial or see plans & pricing